Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could spot cancers that standard scans overlook

NCT ID NCT07118176

Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tracer behaves in the body and whether it can help detect cancers that standard FDG-PET scans might miss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gallium Ga 68 FAPi-46
What this could lead to
If successful, this tracer could improve cancer detection and help doctors see tumors that standard scans might miss.
What could go wrong
This is an early phase 1 study with only 30 participants, so results may not apply broadly. The tracer may not highlight all cancer types effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with the following suspected or diagnosed cancer types: * Adrenal cancer * Anal cancer * Bladder cancer * Brain cancer * Breast cancer * Cancer of unknown primary (CUP) * Cervical cancer * Cholangiocarcinoma * Colorectal cancer * Esophageal cancer * Gastric cancer * Head and neck cancer * Hematologic cancer * Hepatocellular carcinoma * Lung cancer * Medullary thyroid cancer * Neuroendocrine neoplasias * Ovarian cancer * Pancreatic cancer * Penile cancer * Peritoneal cancer * Pleural cancer * Prostate cancer * Sarcoma * Salivary gland cancer * Solitary fibrous tumor * Skin cancer * Testicular cancer * Thymus cancer * Thyroid cancer * Urothelial cancer * Uterus cancer * Vaginal cancer * Patients are ≥ 18 years old at the time of the radiotracer administration * Patient can provide written informed consent * Patient is able to remain still for duration of imaging procedure (up to one hour) Exclusion Criteria: * Patient is pregnant or nursing * Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal gland cancer anal carcinoma anus neoplasm brain cancer breast carcinoma breast neoplasm cancer cancer of unknown primary site carcinoma of esophagus Carcinoma, Medullary cervical carcinoma cholangiocarcinoma colorectal carcinoma colorectal neoplasm Esophageal Neoplasms gastric carcinoma gastric neoplasm head and neck carcinoma hematopoietic and lymphoid system neoplasm hepatocellular carcinoma lung carcinoma lung neoplasm medullary thyroid gland carcinoma neuroendocrine neoplasm ovarian cancer ovarian carcinoma pancreatic adenocarcinoma pancreatic neoplasm penile carcinoma penile neoplasm primary peritoneal carcinoma prostate cancer prostate carcinoma salivary gland cancer salivary gland carcinoma sarcoma skin carcinoma solitary fibrous tumor testicular cancer thymic carcinoma thyroid gland carcinoma Thyroid Neoplasms transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma uterine cancer Uterine Cervical Neoplasms vaginal cancer vaginal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal carcinoma Bladder carcinoma Breast carcinoma Cervical carcinoma Cholangiocarcinoma Colorectal carcinoma Esophageal carcinoma Gastric carcinoma Head and neck carcinoma Hematopoietic and lymphatic system neoplasm Hepatocellular carcinoma Lung carcinoma Malignant adrenal gland neoplasm Malignant brain neoplasm Malignant neoplasm of unknown primary Malignant solid neoplasm Malignant testicular neoplasm Malignant uterine neoplasm Neuroendocrine neoplasm Ovarian carcinoma Pancreatic carcinoma Penile carcinoma Pleural carcinomatosis Primary peritoneal carcinoma Prostate carcinoma Salivary gland carcinoma Sarcoma Skin carcinoma Solitary fibrous tumor Thymus carcinoma Thyroid gland carcinoma Thyroid gland medullary carcinoma Urothelial carcinoma Vaginal carcinoma

Contacts and locations

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.